medigraphic.com
ISSN 0326-3428 (Print)
Órgano de difusión científica de la Asociación Nefrológica de Buenos Aires

2022, Number 2

<< Back Next >>

Rev Nefrol Dial Traspl 2022; 42 (2)

Plasma sTWEAK levels in chronic kidney disease stages

Gok M, Cetinkaya H, Oguz Y

Language: English
References: 17
Page: 103-108
PDF size: 205.78 Kb.


ABSTRACT

Objective: Soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) is a cytokine of the TNF superfamily that has a role in injury of different organs including kidney. We hypothesized that in patients with chronic kidney disease (CKD), sTWEAK levels may be related to endothelial dysfunction that usually accompanies the decline of estimated glomerular filtration rate (eGFR).
Methods: In 199 patients with different stages of CKD we examined the relationship between sTWEAK plasma levels and CKD stages and the relationship between high sensitivity C reactive protein (hs-CRP), homeostatic model assessment of insulin resistance (HOMA-IR) and sTWEAK concentrations.
Results: A gradual decrease in sTWEAK was observed as eGFR decreased. sTWEAK plasma levels were diminished in all stages of CKD and strongly correlated with eGFR. A negative correlation was found between sTWEAK and hs-CRP (p=‹0.001) and while a positive correlation was found between sTWEAK and eGFR (p=‹0.001). No significant correlation was found between sTWEAK and HOMA-IR. In multivariate regression eGFR, diabetes mellitus and hs-CRP parameters were found to be significant independent variables in decreasing plasma sTWEAK levels.
Conclusion: Diminishing of eGFR is accompanied by gradual decreases in sTWEAK plasma levels. Since sTWEAK is strongly and independently correlated with CRP, our study reveals new connections between sTWEAK and endothelial dysfunction in patients with CKD.


REFERENCES

  1. Quiroga B, Verdalles Ú, Reque J, García de VinuesaS, Goicoechea M, Luño J. Cardiovascular events,and mortality in chronic kidney disease (stagesI-IV). Nefrología. 2013;33(4):539-45. doi: 10.3265/Nefrologia.pre2013.May.11895.

  2. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiologyof cardiovascular disease in chronic renal disease. Am JKidney Dis. 1998;32(5 Suppl. 3):S112-9. doi: 10.1053/ajkd.1998.v32.pm9820470.

  3. Endemann DH, Schiffrin EL. Endothelial dysfunction. JAm Soc Nephrol. 2004;15(8):1983-92. doi: 10.1097/01.ASN.0000132474.50966.DA.

  4. Tonelli M, Pfeffer MA. Kidney disease and cardiovascularrisk. Annu Rev Med. 2007;58:123-39. doi: 10.1146/annurev.med.58.071105.111123.

  5. Yilmaz MI, Carrero JJ, Ortiz A, Martín-Ventura JL,Sonmez A, Saglam M, et al. Soluble TWEAK plasmalevels as a novel biomarker of endothelial functionin patients with chronic kidney disease. Clin J AmSoc Nephrol. 2009;4(11):1716-23. doi: 10.2215/CJN.02760409.

  6. Fernández-Laso V, Sastre C, Valdivielso JM, BetriuA, Fernández E, Egido J, et al. Soluble TWEAK andmajor adverse cardiovascular events in patients withCKD. Clin J Am Soc Nephrol. 2016;11(3):413-22. doi:10.2215/CJN.07900715.

  7. Ortiz A, Sanz AB, Muñoz García B, Moreno JA, SánchezNiño MD, Martín-Ventura JL, et al. ConsideringTWEAK as a target for therapy in renal and vascularinjury. Cytokine Growth Factor Rev. 2009;20(3):251-8.doi: 10.1016/j.cytogfr.2009.05.002.

  8. Muntner P, Hamm LL, Kusek JW, Chen J, WheltonPK, He J. The prevalence of nontraditional risk factorsfor coronary heart disease in patients with chronickidney disease. Ann Intern Med. 2004;140(1):9-17. doi:10.7326/0003-4819-140-1-200401060-00006.

  9. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B,Fink NE, et al. Association between cholesterol leveland mortality in dialysis patients: role of inflammationand malnutrition. JAMA. 2004;291(4):451-9. doi:10.1001/jama.291.4.451.

  10. National Kidney Foundation. Chronic Kidney Disease,Classification [Internet]. Disponible en: (consulta: 28/01/2021).

  11. Kralisch S, Ziegelmeier M, Bachmann A, SeegerJ, Lössner U, Blüher M, et al. Serum levels of theatherosclerosis biomarker sTWEAK are decreasedin type 2 diabetes and end-stage renal disease.Atherosclerosis. 2008;199(2):440-4. doi: 10.1016/j.atherosclerosis.2007.10.022.

  12. Fernández-Laso V, Méndez-Barbero N, Valdivielso JM,Betriu A, Fernández E, Egido J, et al. Soluble TWEAKand atheromatosis progression in patients with chronickidney disease. Atherosclerosis. 2017;260:130-7. doi:10.1016/j.atherosclerosis.2017.03.043.

  13. Winkles JA. The TWEAK-Fn14 cytokine-receptoraxis: discovery, biology, and therapeutic targeting. NatRev Drug Discov. 2008;7(5):411-25. doi: 10.1038/nrd2488.

  14. Carrero JJ, Ortiz A, Qureshi AR, Martín-VenturaJL, Bárány P, Heimbürger O, et al. Additive effectsof soluble TWEAK and inflammation on mortalityin hemodialysis patients. Clin J Am Soc Nephrol.2009;4(1):110-8. doi: 10.2215/CJN.02790608.

  15. Blanco-Colio LM, Martín-Ventura JL, Muñóz-GarcíaB, Orbe J, Páramo JA, Michel JB, et al. Identificationof soluble tumor necrosis factor-like weak inducerof apoptosis (sTWEAK) as a possible biomarkerof subclinical atherosclerosis. Arterioscler ThrombVasc Biol. 2007;27(4):916-22. doi: 10.1161/01.ATV.0000258972.10109.ff.

  16. Shi X, Qiu B, Shen H, Feng S, Fu J. Inverserelationship between plasma tumor necrosis factor-likeweak inducer of apoptosis and carotid intima-mediathickness among patients undergoing hemodialysis andperitoneal dialysis. Cardiorenal Med. 2020;10(3):137-44. doi: 10.1159/000503811.

  17. Hénaut L, Sanz AB, Martin-Sanchez D, CarrascoS, Villa-Bellosta R, Aldamiz-Echevarria G, et al.TWEAK favors phosphate-induced calcification ofvascular smooth muscle cells through canonical andnon-canonical activation of NFκB. Cell Death Dis.2016;7(7):e2305. doi: 10.1038/cddis.2016.220.




2020     |     www.medigraphic.com